Home › All Companies › ACRV › Annual Report

Acrivon Therapeutics, Inc. (ACRV) — Annual Report

AI-Powered SEC Filing Analysis

← All ACRV filings
Latest Annual Report Filed: 2026-03-19

Key Insights

  • Acrivon Therapeutics, Inc. (ACRV) filed its 10-K report for the fiscal year 2025, providing insights into the company's financial performance and operational activities.
  • The report indicates that Acrivon Therapeutics is focused on the development of its lead drug candidates, ACR368 and ACR2316, as well as its other drug discovery programs.
  • The company has entered into several key agreements, including the Lilly Agreement and the Akoya Agreement, which may provide additional financial resources and collaborative opportunities.
Sentiment: Positive Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-19. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Acrivon Therapeutics, Inc.

Insider Trading Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.